Prime Medicine: High-Risk, High-Reward Bet on Next-Gen Gene Editing with Game-Changing, But Unproven, Prime Editing Platform
Overview
Prime Medicine is a biotechnology innovator at the leading edge of gene therapy, utilizing its proprietary Prime Editing technology to tackle a vast range of human genetic diseases. Unlike CRISPR/Cas9, Prime Editing claims the precision to correct ~90% of pathogenic genetic mutations, promising one-time, potentially curative therapies over a variety of cell types and organs. Founded in 2019 by Dr. David Liu and supported by exclusive IP from the Broad Institute, Prime’s early programs target rare genetic diseases in hematology, liver, and lung applications—with recent clinical progress marked by the first-ever clinical dose of a Prime Editor in 2024. Backed by notable scientific and strategic partnerships, the company is positioned to transform treatment paradigms for genetic disorders, albeit with clinical studies in the earliest stages.